Bridgebio Pharma, Inc. (BBIO) Stock Price & Analysis

Bridgebio Pharma, Inc. (BBIO) rose 0.46% to USD 67.68 as of June 9, 2026 at 23:55 UTC, according to Nexqual real-time market data.

BBIO last closed at USD 67.37; the session ranged USD 65.83–69 on volume of 1,808,463 shares. Market capitalization is $13.26B, with a 52-week range of USD 38.58–84.94 (NMS). Source: Nexqual, June 9, 2026 at 23:55 UTC.

Key Statistics (as of June 9, 2026 at 23:55 UTC)

Technical Analysis (BBIO)

Nexqual's technical model rates BBIO "NEUTRAL" based on 2 bullish and 3 bearish signals across 124 daily candles, as of June 9, 2026 at 23:55 UTC.

Analyst Ratings (BBIO)

Wall Street analysts rate BBIO "Strong Buy" based on 23 analysts, with a mean price target of USD 102.71 (range USD 76–157), per Nexqual as of June 9, 2026 at 23:55 UTC.

Earnings (BBIO)

Recent Earnings History

Source: Nexqual, June 9, 2026 at 23:55 UTC.

Financials & Fundamentals (BBIO)

Source: Nexqual, June 9, 2026 at 23:55 UTC.

Financial Health Score (BBIO)

Nexqual rates Bridgebio Pharma, Inc.'s overall financial health "Mixed" across five dimensions, as of June 9, 2026 at 23:55 UTC.

Ownership (BBIO)

Source: Nexqual, June 9, 2026 at 23:55 UTC.

Leadership (BBIO)

Bridgebio Pharma, Inc. is led by Neil Kumar (age 46), Co-Founder, CEO & Director, per Nexqual as of June 9, 2026 at 23:55 UTC.

Major Backers & Investors (BBIO)

Notable institutional backers of Bridgebio Pharma, Inc. include Kohlberg Kravis Roberts & Co. L.P., Janus Henderson Group PLC, Viking Global, according to Nexqual as of June 9, 2026 at 23:55 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, June 9, 2026 at 23:55 UTC.

From Bridgebio Pharma, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• This efficiency allows us to work on a broad range of scientifically compelling therapies, including programs for underserved conditions which more traditional biopharmaceutical models might leave on the shelf but we believe can be developed on a Net Present Value ("NPV")-positive basis in our portfolio.
• This portfolio-based approach allows us to advance multiple programs in parallel and, over time, support a self-reinforcing "flywheel" of portfolio development.
• The following graphic illustrates our approach to program selection: Exhibit 1 1 As shown in Exhibit 1 above, we apply a quantitative approach to evaluating our programs and our Company as a whole, which typically includes the following factors: • Scientifically grounded program selection: Each program is selected based on strong biological validation, including a clear understanding of disease mechanism and a therapeutic approach designed to address a well-defined genetic condition.
• This model is intended to allow multiple programs to advance concurrently while enabling capital and other resources to be allocated flexibly as data evolves, consistent with our approach to managing development risk over time.

Partnerships

• We have licensed commercial rights in Europe to Bayer who are commercializing Beyonttra in all EU member states, the United Kingdom, Switzerland and Turkey under our Exclusive License Agreement with Bayer signed in March 2024.
• Outside the United States, acoramidis is marketed as Beyonttra™ and is commercialized through strategic collaboration partners, including Bayer in Europe and Alexion in Japan, as well as directly by BridgeBio in certain international markets.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 9, 2026 at 23:55 UTC. This page is informational and not investment advice.